Teriparatide for osteoporosis: importance of the full course
Teriparatide (TPTD) is the only currently available therapeutic agent that increases the formation of new bone tissue and can provide some remediation of the architectural defects in the osteoporotic skeleton. The use of teriparatide clinically is limited to 24 months. We review clinical findings du...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer London
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947115/ |